Nuvalent Inc (NASDAQ:NUVL)’s share price fell 6.6% during trading on Tuesday . The company traded as low as $33.34 and last traded at $33.35. 3,521 shares traded hands during trading, a decline of 99% from the average session volume of 249,310 shares. The stock had previously closed at $35.70.
A number of research firms have commented on NUVL. Piper Sandler began coverage on Nuvalent in a research note on Monday, August 23rd. They set an “overweight” rating and a $40.00 price objective on the stock. Cowen began coverage on Nuvalent in a report on Monday, August 23rd. They issued an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. began coverage on Nuvalent in a report on Monday, August 23rd. They issued an “overweight” rating and a $34.00 target price on the stock.
Nuvalent (NASDAQ:NUVL) last released its quarterly earnings data on Wednesday, September 8th. The company reported ($3.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($2.97). Equities research analysts expect that Nuvalent Inc will post -1.25 earnings per share for the current fiscal year.
Nuvalent Inc is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company’s program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc is based in CAMBRIDGE, Mass.
See Also: What are economic reports?
Receive News & Ratings for Nuvalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvalent and related companies with MarketBeat.com's FREE daily email newsletter.